Vigabatrin-induced modification of Ki-67 expression in gingival epithelium: Immunohistochemical study of a short series

Journal of Periodontal Research

Volumn 39, Issue 1, 2004, Pages 66-71

  Mesa, F ^a   Aguilar, M ^b   Gonzalez Moles, M A ^a   Guerrero, A ^c   Sanchez Alvarez, J C ^d   Del Moral, R G ^b   O'Valle, F ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Gingival enlargement; Ki 67; p21 waf1; p27kip1; p53; Vigabatrin

Indexed keywords

ANTICONVULSIVE AGENT; CD3 ANTIGEN; CD38 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P21; PROTEIN P27; PROTEIN P53; VIGABATRIN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; ENZYME INHIBITOR; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE; CHEMICAL MODIFICATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; EPITHELIUM; EVALUATION; FEMALE; FOCAL EPILEPSY; GINGIVA DISEASE; GINGIVA HYPERTROPHY; GINGIVAL BIOPSY; HEALTH STATUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LAMINA PROPRIA; MALE; PERIODONTAL DISEASE; SEIZURE; T LYMPHOCYTE; CELL DIVISION; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; GINGIVA; GINGIVA OVERGROWTH; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PLASMA CELL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; GINGIVA; GINGIVAL OVERGROWTH; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; PERIODONTAL DISEASES; PLASMA CELLS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIGABATRIN;

EID: 1542652945     PISSN: 00223484     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2004.00711.x     Document Type: Article

References (23)

1. Katz J, Givol N, Chaushu G, Taicher S, Shemer J. Vigabatrin induced gingival overgrowth. J Clin Periodontol 1997;24: 180-182.
2. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998;50:614-618.
3. Mesa FL, López-Leyva C, González-Moles MA. Del Moral R, O'Valle FJ. Agrandamiento gingival por vigabatrina. Descripción clínica e histopatológica de un nuevo caso. Med Oral 2000;5:133-137.
4. Saito K, Mori S, Tanda N, Sakamoto S. Expression of p53 and Ki-67 antigen in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontol 1999;70:581-586.
5. Nurmenniemi PK, Pernu HE, Knuuttila ML. Mitotic activity of keratinocytes in nifedipine- and immunosuppressive medication-induced gingival overgrowth. J Periodontol 2001;72:160-166.
6. Inglés E, Rossmann JA, Caffesse RG. New clinical index for drug-induced gingival overgrowth. Quintessence Int 1999;30:467-473.
7. O'Leary TJ, Drake RB, Naylor JE. The plaque control record. J Periodontol 1972; 43:38.
8. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229-233.
9. Mesa F, Masseroli M, López C, Revelles F, O'Valle F. Valoración morfométrica del epitelio gingival. Cuantificación de los cambios morfológicos mediante análisis digital de imagen. Arch Odonto Estomatol 1997;13:652-660. http://www.conganat.org/ icongreso/comunic/com086/titulo.htm
10. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. On the mechanism of DIGH. J Oral Pathol Med 1991;20:201-209.
11. Gregoriou AP, Schneider PE, Shaw PR. Phenobarbital-induced gingival overgrowth? Report of two cases and complications in management. ASDC J Dent Child 1996;63:408-413.
12. Anderson HH, Rapley JW, Williams DR. Gingival overgrowth with valproic acid: a case report. ASDC J Dent Child 1997;64:294-297.
13. Marshall RI, Bartold PM. Medication induced gingival overgrowth. Oral Dis 1998;4:130-151.
14. O'Valle F, Mesa F, Gómez-Morales M et al. Immunohistochemical study of 30 cases of cyclosporin A-induced gingival overgrowth. J Periodontol 1994;65:724-730.
15. González-Jaranay M, Mesa FL. Hiperplasia gingival inducida por nifedipino. Rev Eur Odontoestomatol 1991;3:127-130.
16. Gerdes J, Lemke M, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-65. J Immunol 1984;133:1710-1715.
17. Lloyd RV, Erickson LA, Jin L et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999;154:313-323.
18. Porter PL, Malone KE, Heagerty PJ et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3: 152-154.
19. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol 1999; 23:288-295.
20. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701.
21. Gottlieb TM, Oren M. P53 in growth control and neoplasia. Biochim Biophys Acta 1996;1287:77-102.
22. Pillai G, Roberts H, Gatter K, Pezzella F. P53 expression in normal paraffin-embedded tissue using different antibodies and antigen retrieval buffer systems. Histopathology 2003;42:83-87.
23. Pernu HE, Knuuttila ML. Macrophages and lymphocyte subpopulations in nifedipine- and cyclosporin A-associated human gingival overgrowth. J Periodontol 2001;72:160-166.